Podcasts about california san diego

First up on the podcast, increased carbon dioxide emissions sink more acidity into the ocean, but checking pH all over the world, up and down the water column, is incredibly challenging. Staff Writer Paul Voosen joins host Sarah Crespi to discuss a technique that takes advantage of how sound moves through the water to detect ocean acidification. Next on the show, we visit the lab of University of California San Diego professor Alysson Muotri at the Sanford Consortium, where he grows human brain organoids—multicellular structures that function like underdeveloped brains. Muotri used organoids to compare a protein that appears to be protective in human brains against the effects of lead toxicity with the archaic version of the protein that was present in our extinct cousins, like Denisovans and Neanderthals. His work suggests lead exposure differently affected our ancestors and our archaic cousins, possibly helping us survive to the present day. Finally, stay tuned for the last in our six-part series on books exploring the science of death. This month, host Angela Saini talks with astrophysicist Katie Mack about how the universe might end and her 2021 book The End of Everything: (Astrophysically Speaking). This week's episode was produced with help from Podigy. Learn more about your ad choices. Visit megaphone.fm/adchoices

First up on the podcast, increased carbon dioxide emissions sink more acidity into the ocean, but checking pH all over the world, up and down the water column, is incredibly challenging. Staff Writer Paul Voosen joins host Sarah Crespi to discuss a technique that takes advantage of how sound moves through the water to detect ocean acidification. Next on the show, we visit the lab of University of California San Diego professor Alysson Muotri at the Sanford Consortium, where he grows human brain organoids—multicellular structures that function like underdeveloped brains. Muotri used organoids to compare a protein that appears to be protective in human brains against the effects of lead toxicity with the archaic version of the protein that was present in our extinct cousins, like Denisovans and Neanderthals. His work suggests lead exposure differently affected our ancestors and our archaic cousins, possibly helping us survive to the present day. Finally, stay tuned for the last in our six-part series on books exploring the science of death. This month, host Angela Saini talks with astrophysicist Katie Mack about how the universe might end and her 2021 book The End of Everything: (Astrophysically Speaking). This week's episode was produced with help from Podigy. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this essential episode of Parallax, Dr Ankur Kalra welcomes Dr Monica Tincopa, Assistant Professor of Medicine at the University of California San Diego, for a crucial conversation about Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its profound implications for cardiovascular care. Dr Tincopa guides listeners through the recent transformation from NAFLD to MASLD, explaining why this nomenclature change represents more than just terminology, instead reflecting a deeper understanding of metabolic health that directly impacts cardiology practice. The conversation explores practical screening strategies that cardiologists can implement immediately, including the use of FIB-4 risk stratification and recognizing incidental findings on cardiac imaging. Dr Tincopa shares insights on when to refer patients to hepatology specialists and how the shared risk factors between MASLD and cardiovascular disease create opportunities for comprehensive patient care. This episode equips cardiologists with essential knowledge to identify at-risk patients within their existing practice, understand the cardiovascular implications of liver disease, and optimize care coordination for patients with overlapping metabolic conditions. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who's on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe conversation covers the efficacy and safety of checkpoint inhibitors like pembrolizumab, the importance of a multidisciplinary approach, and the challenges of balancing systemic and localized treatments. They also touch upon the potential future role of biomarkers in reducing invasive procedures and improving patient outcomes.---TIMESTAMPS00:00 - Introduction02:04 - The Role of Medical Oncologists in Bladder Cancer12:58 - Combination Therapies and Patient Outcomes21:18 - The CREST Study26:59 - Managing Adverse Events34:44 - Collaboration Between Urologists and Oncologists41:06 - Conclusion and Final Thoughts---RESOURCESCREST Trialhttps://www.nature.com/articles/s41591-025-03738-zCISTO Studyhttps://pubmed.ncbi.nlm.nih.gov/37980511/

Have you ever found yourself holding onto feelings of guilt or shame long after a difficult experience or mistake? In this episode, Jill sits down with Dr. Carolyn Allard, a leading voice in trauma-focused psychology and research. Together, they unpack the complex nature of guilt and shame, especially when these emotions become non-adaptive in the face of trauma or hardship. Carolyn, who is also the author of Transform Your Guilt and Shame: Evidence-Based Strategies to Heal from Trauma and Adversity, shares how to recognize the difference between guilt and shame and introduces the idea of “non-adaptive guilt and shame” (NAGS). You'll gain insight into how these emotions link to moral injury and other trauma responses, and walk away with actionable tools such as hindsight bias and justification analysis to better understand, challenge, and manage them.Listen and Learn: How guilt and shame differ lies in focus, as guilt is about actions and shame is about identity, and why they matterHow moral injury can emerge from situations where individuals face impossible choices that conflict with their values, leading to lasting feelings of guilt and shameWhy we feel non-adaptive guilt and shame often comes down to distorted beliefs about responsibility, justification, and values, and how understanding these patterns helps us break free from self-blame and move toward self-compassionHow hindsight bias can trick us into unfair self-judgment, and by reflecting on our choices and context at the time, we can gain a clearer, kinder perspectiveUnderstanding the difference between accountability (being answerable) and responsibility (having control or intention) and how this helps us untangle guilt and shame, process mistakes effectively, and break the self-reinforcing cycles of trauma that impair our ability to act according to our valuesResources: Transform Your Guilt and Shame: Evidence-Based Strategies to Heal from Trauma and Adversity: https://bookshop.org/a/30734/9781433843419 Carolyn's Website: https://www.carolynallardphd.com/Connect with Carolyn on Social Media: Bluesky: https://bsky.app/profile/carolynallardphd.bsky.social Facebook:https://www.facebook.com/p/Carolyn-Allard-PhD LinkedInhttps://www.linkedin.com/in/carolyn-allard-99749155/About Carolyn B. AllardCarolyn B. Allard ,PhD, ABPP, is internationally recognized for her trauma-focused research and clinical expertise. She is a licensed, board-certified clinical psychologist, Distinguished Professor and Program Director of the Clinical Psychology PhD Program at Alliant International University. Before that, she directed a trauma clinic at the VA San Diego Healthcare System and served as clinical faculty at the University of California San Diego. Carolyn also serves on the executive council of the American Psychological Association's Trauma Division and its scientific journal's editorial board, and has over 200 scientific publications and presentations. For over 20 years, she has been providing therapy, training and consultation in empirically supported therapy for posttraumatic distress; and conducting research focused on socio-cultural and contextual predictors of posttraumatic distress and treatment outcomes. She co-developed Trauma Informed Guilt Reduction (TrIGR), the evidence-based therapy that is the basis of her latest book, Transform Your Guilt and Shame, a self-guided workbook. Besides making psychology accessible, Carolyn is passionate about traveling and promoting compassion. Visit CarolynAllardPhD.com for more information.Related Episodes:118. Moral Injury and Shame with Lauren Borges and Jacob Farnsworth416. Trauma and PTSD Treatment with Robyn Walser383. What My Bones Know: C-PTSD with Stephanie Foo417. Busting Trauma Treatment Myths with Emi Nietfeld405. Taming the Inner Critic with Holly Yates and Shawn Whooley341. Self-Forgiveness with Grant Dewar279. ACT for Healing Black Racial Trauma with Jennifer Shepard PayneSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This series of Voices of Student Success focuses on the use of generative artificial intelligence in higher education and how technology can support student success goals.   While AI tools have proliferated in education and workplace settings, not all tools are free or accessible to students and staff, which can create equity gaps regarding who is able to participate and learn new skills. To address this gap, San Diego State University leaders created an equitable AI alliance in partnership with the University of California San Diego and the San Diego Community College District. Together, the institutions work to address affordability and accessibility concerns for AI solutions, as well as share best practices, resources and expertise.  In the latest episode of Voices of Student Success, James Frazee, San Diego State University's chief information officer, discusses the alliance and SDSU's approach to teaching AI skills to students.  Hosted by Inside Higher Ed Student Success reporter Ashley Mowreader, this episode is sponsored by TimelyCare.  Read a transcript of the podcast here. 

In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jason Silverman talk to Dr. Amber Hildreth, pediatric gastroenterologist and transplant hepatologist at Rady Children's Hospital and Assistant Professor at the University of California San Diego. She is also a clinician scientist at the Rady Children's Institute for Genomic Medicine. We discuss how genetic testing is transforming the way we care for children with rare GI and liver diseases.Learning objectivesRecognize key differences between various types of genetic testing.Discuss several applications of genetic testing in care for children with GI disorders.Understand the role of the genetic counselor in integrating genetic testing into GI practice.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Southern Oregon University Percussion Professor Terry Longshore stops by to talk about his job at the University, building a program, and his very active chamber and freelancing performance career (02:35), growing up in Fresno (CA) and his early background on a variety of instruments (32:20), attending Fresno State University for his first undergrad degree, playing regular gigs, and what he learned majoring in computer programming (42:40), his non-music job out of undergrad, then heading to Sacramento State (CA) to study music (56:40), his time as a grad student at the University of California-San Diego and learning under the mentorship of Steven Schick (01:07:30), his first teaching position in North Dakota and how he negotiated for a better job title (01:19:15), and settles in for the Random Ass Questions, including segments on percussion stereotypes, impressions, challenging circumstances, making hummus, wedding songs, great movies and books, and being inspired by music he's currently performing (01:26:45).Finishing with a Rave on the 2013 film About Time (01:59:15).Terry Longshore Links:Terry Longshore's websiteTerry Longshore's SOU pageTerry Longshore's Marimba One page'Rogue Valley SymphonyPrevious Podcast Guests mentioned:Steven Schick in 2025Hannah Weaver in 2021Other Links:Tessa BrinckmanGrant RuizJuri SeoShawn GlydeDavid GlydeGuide to Teaching Percussion - Ronald HollowayDaniel Kennedy“Third Construction” - John Cage“Synchronisms No. 5” - Mario DavidovskyGeorge LewisMiller PucketteBeginners trailerA Fine Balance - Rohinton MistryThe River Why - David James DuncanBraiding Sweetgrass - Robin Wall KimmererJustin DeHart“Got My Mind Set on You” - George HarrisonHow to Read a Book - Monica Wood"Losing Earth” - Adam SchoenbertRaves:About Time trailer

Jessie Rain Anne Smith is a Qualified Mindfulness-Based Stress Reduction (MBSR) Teacher, trained through the University of California San Diego's Mindfulness-Based Professional Training Institute. She has also completed Dr. David Treleaven's Trauma-Sensitive Mindfulness training, and was one of a select few chosen by Dr. Treleaven for mentorship in 2022.Episode Summary:In this episode of the Concussion Coach Podcast, Bethany Lewis welcomes Jessie Rain Smith, a Mindfulness-Based Stress Reduction (MBSR) teacher and founder of Mindful Concussion. Following her own car accident and brain injury in 2013, Jessie was advised to use mindfulness but discovered that while some practices were incredibly powerful, others were detrimental, leading to panic and dissociation.Jessie shares her personal concussion journey and the realization that recovery can be a long, winding path. She and Bethany dive into a crucial discussion on the dual nature of mindfulness for the injured brain. They explore its profound benefits for attention, nervous system regulation, and emotional control, while also highlighting the potential perils of common practices like body scans and intense interoceptive awareness that can be overly cognitive or dysregulating.Jessie explains her modified approach, which prioritizes "nurturing anchors of attention" and "concentration practices" to build safety and regulation before moving into more challenging work. This episode is an essential listen for anyone in the brain injury community—survivors and caregivers alike—looking to harness the healing power of mindfulness in a safe, effective, and trauma-informed way.Key Discussion Points:Jessie's Concussion Story: The onset of symptoms days after her car accident and her journey through the healthcare system.The Surprise of Prolonged Symptoms: The realization at 2.5 years post-injury that recovery was not linear and required a fundamental shift in lifestyle and activity levels.The Role of the Nervous System: How a pre-existing state of dysregulation (e.g., from previous trauma) can influence concussion recovery.Defining Mindfulness: Moving from being "lost in thought" (worries, regrets) to landing in the present moment.The Power of Mindfulness for brain injury:Attentional Control: Practicing the muscle of bringing focus back to the present, which is directly beneficial for cognitive fatigue and focus issues.Nervous System Regulation: Learning that symptoms are not a threat, moving away from the "fight, flight, or freeze" response (faulty neuroception).Resources Mentioned: Jessie's Website: www.mindfulconcussion.caSign up for her free bi-monthly Zoom mindfulness sessions for survivors.Read her blog (including the post on mindful chocolate eating!).Jessie's Upcoming Book: The Power and Perils of Mindfulness for Brain Injury (To be released). Follow her on social media for updates and to give feedback on drafts.Trauma-Sensitive Mindfulness: The work of Dr. David Treleaven (davidtreleaven.com), author of Trauma-Sensitive Mindfulness: Practices for Safe and Transformative Healing.Free Guide from Bethany: "The 5 Best Ways to Support Your Loved One Dealing with a Concussion." Available at www.theconcussioncoach.com.Bethany's Coaching Program: For a free consultation on her concussion coaching program, visit www.theconcussioncoach.com.Viktor Frankl quote: "Between stimulus and response there is a space. In that space is our power to choose our response. In our response lies our growth and our freedom."Connect with the Guest:Website: mindfulconcussion.caEmail: jessie@mindfulconcussion.caSocial Media: Follow Jessie on LinkedIn and Facebook for updates on her book and to participate in her social media feedback campaign.Disclaimer: The information in this podcast is for educational and awareness purposes only and is not intended as medical advice. Please consult with your healthcare provider for any medical concerns.

New survival data from the FLAURA2 and MARIPOSA trials represent “a massive advance for our patients” in terms of frontline treatment for EGFR-mutated non-small cell lung cancer says Sandip P. Patel, MD, professor of medicine at the University of California San Diego. However, the findings have led to new questions about sequencing. “Just like in chess, when you make a move, you're restricted in the moves that you can make afterward,” he explains to Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair. Discussions have become “much more nuanced,” and “thinking about the patient holistically becomes even more important in the setting of all these excellent treatment options for our patients,” Dr. Patel shares. Dr. Patel reported scientific advisory income from Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina, Merck, Pfizer, Natera, and Tempus. Dr. Figlin reported various financial relationships.

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

First up on the podcast, Staff Writer Rodrigo Pérez Ortega joins host Sarah Crespi to talk about a megafauna megafind that rivals the La Brea Tar Pits. In addition to revealing tens of thousands of bones from everything from dire wolves to an ancient human, the site has yielded the first DNA from ammoths that lived in a warm climate.    Next on the show, the Tijuana River crosses the U.S.-Mexican border from Tijuana to San Diego—bringing with it sewage, industrial waste, and stinky smells. News Intern Nazeefa Ahmed talks with Kimberly Prather, an atmospheric chemist at the University of California San Diego about detecting both air and water pollution around the river and the steps needed for cleanup.   Finally, the latest in our series of books exploring the science of death. This month, host Angela Saini talks with philosopher Susana Monsó about her ook Playing Possum: How Animals Understand Death. Content warning for this segment: The interview contains descriptions of dead baby animals.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Sarah Crespi; Rodrigo Perez Ortega; Angela Saini Learn more about your ad choices. Visit megaphone.fm/adchoices

First up on the podcast, Staff Writer Rodrigo Pérez Ortega joins host Sarah Crespi to talk about a megafauna megafind that rivals the La Brea Tar Pits. In addition to revealing tens of thousands of bones from everything from dire wolves to an ancient human, the site has yielded the first DNA from ammoths that lived in a warm climate.    Next on the show, the Tijuana River crosses the U.S.-Mexican border from Tijuana to San Diego—bringing with it sewage, industrial waste, and stinky smells. News Intern Nazeefa Ahmed talks with Kimberly Prather, an atmospheric chemist at the University of California San Diego about detecting both air and water pollution around the river and the steps needed for cleanup.   Finally, the latest in our series of books exploring the science of death. This month, host Angela Saini talks with philosopher Susana Monsó about her ook Playing Possum: How Animals Understand Death. Content warning for this segment: The interview contains descriptions of dead baby animals.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Sarah Crespi; Rodrigo Perez Ortega; Angela Saini Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Ganesh Anand is an Associate Professor of Chemistry as well as Biochemistry and Molecular Biology at The Pennsylvania State University (or Penn State University) at the University Park campus. He is also an elected Board Member of the International Society for Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS). Research in Ganesh's lab examines molecular switches. He wants to know how molecules interact with one another and how they switch from one state to another. These tiny molecular switches act almost like electrical switches turning on and off the functions of different molecules. He also does research on viruses and how they change shape to infect their hosts. Beyond his scientific interests, Ganesh has also been passionate about music for as long as he can remember. He takes voice lessons now and enjoys singing in choirs in his free time. He received his bachelor's degree in pharmacy and his master's degree in biological sciences from Birla Institute of Technology and Science in India. Next, Ganesh attended Rutgers University where he earned his PhD in biochemistry. Afterwards, he conducted postdoctoral research as a Howard Hughes Medical Institute Research Fellow at the University of California San Diego. Ganesh served on the faculty in the Department of Biological Sciences at the National University of Singapore for over a decade before accepting a faculty position at Penn State where he is today. His lab is recognized as a Waters World Center of Innovation in Hydrogen/Deuterium Exchange Mass Spectrometry. Ganesh is founding member and former Director of the Singapore National Laboratory for Mass Spectrometry (SingMass) and the former Vice President of the Singapore Society for Mass Spectrometry. In this interview, he shares more about his life and science.

Mini-brains in space. Did you know that we can study something called brain organoids, effectively mini-brains, in the special conditions in space, on the International Space Station, and that such studies may help us with diseases like Alzheimers, Autism or Parkinsons? My guest this week is Prof. Alysson Muotri from the University of California San Diego. He and his team have flown such brain organoids to the ISS many times already. Don't miss this episode on what I consider one of the most exciting intersections of space and biology, and ultimately a potential source of massive positive impact right here on Earth!

Dr. Benjamin Bergen is a Cognitive Science professor at the University of California San Diego, the author of the book, What the F, and was featured on the Netflix series “The History of Swear Words.” Here he shares what makes a word bad, discusses the future of cussing, the efficacy of word prohibition & the cultural influence of cursing etymology around the world.This episode originally aired August 22, 2022.If you like this episode, you'll also like episode 245: IS SKIPPING SMALL TALK AN OPTION? UBERS, ELEVATORS & FAMILY [REMASTERED]Guest: https://www.linkedin.com/in/ben-bergen-a89b763/  | https://www.amazon.com/Benjamin-K-Bergen/e/B00DVR8POC/ref=aufs_dp_fta_dskHost:  https://www.meredithforreal.com/  | https://www.instagram.com/meredithforreal/  | meredith@meredithforreal.com | https://www.youtube.com/meredithforreal  | https://www.facebook.com/meredithforrealthecuriousintrovert Sponsors: https://www.jordanharbinger.com/starterpacks/ | https://uwf.edu/university-advancement/departments/historic-trust/

Is your engineering team running like the wild, wild west? What does engineering excellence look like in practice?In this episode, Ganesh Datta, co-founder and CTO of Cortex, explores what it takes to achieve engineering excellence. Ganesh shares lessons from his own journey, from early bug-fixing to building a company focused on engineering excellence.We discuss how platform engineering and internal developer platforms (IDPs) can help teams scale, improve reliability, and align with business outcomes. Ganesh also explains why culture, leadership, and clear metrics matter more than any single tool.If you're looking to make your engineering team a true business driver, this conversation is for you.Key topics discussed:How to define engineering excellence and why it's tied to business outcomes.The critical role of leadership in connecting engineering initiatives to business values.When to invest in platform engineering and internal developer platforms as your team grows.Common misconceptions about platform engineering.The importance of clear metrics, shared language, and transparency for continuous improvement.Building a culture that supports operational excellence through rituals and repeated messaging.Real-world examples of using generative AI to accelerate platform adoption and incident analysis.Timestamps:(00:00) Trailer & Intro(01:56) Career Turning Points(07:50) The Practice of Finding the Patterns in Issues(11:39) The Definition of Engineering Excellence(17:10) The Leader's Role in Engineering Excellence(22:31) Aligning Engineering Excellence with the Business Outcomes(26:30) The Importance of Metrics in Engineering Excellence(33:35) The Culture that Drives Engineering Excellence(39:05) Platform Engineering and Internal Developer Platform(45:02) The Biggest Misconception of Platform Engineering or IDP(50:36) Cortex as an Engineering Excellence Platform(52:39) Generative AI Use Case in Platform Engineering(55:26) 3 Tech Lead Wisdom_____Ganesh Datta's BioGanesh Datta is a Co-Founder & CTO of Cortex. Before co-founding Cortex, he was a Principal Software Engineer at Mission Lane where he was responsible for driving the development of real-time underwriting infrastructure. At LendUp, Ganesh was a Senior Software Engineer leading the development and optimization of the company's decisioning infrastructure and financial account management system. Ganesh holds a bachelor of science in computer science from the University of California San Diego.Follow Ganesh:LinkedIn – linkedin.com/in/gsdattaTwitter – x.com/gsdattaWebsite – www.cortex.ioEmail – ganesh@cortex.ioJoin Ganesh & Cortex at IDPCon in NYC – ipdcon.comLike this episode?Show notes & transcript: techleadjournal.dev/episodes/225.Follow @techleadjournal on LinkedIn, Twitter, and Instagram.Buy me a coffee or become a patron.

We are still learning about all the effects of cannabis use. Raphael Cuomo, professor of medicine at the University of California, San Diego, explores how it may tie in with one affliction. Raphael E. Cuomo, PhD, is a globally recognized authority in biomedical science and non-communicable disease epidemiology. His research has shaped how scientists and […]

Professor Gert Cauwenberghs has been working toward building brain-scale systems for decades. At the University of California San Diego, he's now one of the leaders of the Neuromorphic Commons hub, also known as Thor, which will give the wider community access to neuromorphic hardware and simulators. In this episode of Brains and Machines, he talks to Dr. Sunny Bains of University College London about his approach to making systems that use minimal energy, are highly interconnected at all levels, and are surprisingly flexible. Discussion follows with Dr. Giulia D'Angelo from the Czech Technical University in Prague and Professor Ralph Etienne-Cummings of Johns Hopkins University.

The Open Society as an Enemy: A critique of how free societies turned against themselves by J. McKenzie Alexander Nearly 80 years ago, Karl Popper gave a spirited philosophical defence of the Open Society in his two-volume work, The Open Society and Its Enemies. In this book, J. McKenzie Alexander argues that a new defence is urgently needed because, in the decades since the end of the Cold War, many of the values of the Open Society have come under threat once again. Populist agendas on both the left and right threaten to undermine fundamental principles that underpin liberal democracies, so that what were previously seen as virtues of the Open Society are now, by many people, seen as vices, dangers, or threats. The Open Society as an Enemy: A Critique of how Free Societies Turned Against Themselves interrogates four interconnected aspects of the Open Society: cosmopolitanism, transparency, the free exchange of ideas, and communitarianism. Each of these is analysed in depth, drawing out the implications for contemporary social questions such as the free movement of people, the erosion of privacy, no-platforming and the increased political and social polarisation that is fuelled by social media. In re-examining the consequences for all of us of these attacks on free societies, Alexander calls for resistance to the forces of reaction. But he also calls for the concept of the Open Society to be rehabilitated and advanced. In doing this, he argues, there is an opportunity to re-think the kind of society we want to create, and to ensure it is achievable and sustainable. This forensic defence of the core principles of the Open Society is an essential read for anyone wishing to understand some of the powerful social currents that have engulfed public debates in recent years, and what to do about them. The book is publicly available via the following link The Open Society as an Enemy | LSE Press J. McKenzie Alexander is a Professor in Philosophy at the Department of Philosophy, Logic and Scientific Method in the London School of Economics. From 2012 to 2018, Professor Alexander served as one of the Academic Governors on the Council of the LSE, as well as a member of the Court of Governors. From 2018–2021, he served as the Head of Department. Before joining the department, Alexander was a Visiting Assistant Professor at the Department of Philosophy, University of California – San Diego (between 2000 and 2001). Although J. McKenzie Alexander's original field of research concerned evolutionary game theory as applied to the evolution of morality and social norms, more recently he has worked on problems in decision theory, more broadly construed, including topics in formal epistemology. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube Channel: https://www.youtube.com/user/a48266/videos Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

The Open Society as an Enemy: A critique of how free societies turned against themselves by J. McKenzie Alexander Nearly 80 years ago, Karl Popper gave a spirited philosophical defence of the Open Society in his two-volume work, The Open Society and Its Enemies. In this book, J. McKenzie Alexander argues that a new defence is urgently needed because, in the decades since the end of the Cold War, many of the values of the Open Society have come under threat once again. Populist agendas on both the left and right threaten to undermine fundamental principles that underpin liberal democracies, so that what were previously seen as virtues of the Open Society are now, by many people, seen as vices, dangers, or threats. The Open Society as an Enemy: A Critique of how Free Societies Turned Against Themselves interrogates four interconnected aspects of the Open Society: cosmopolitanism, transparency, the free exchange of ideas, and communitarianism. Each of these is analysed in depth, drawing out the implications for contemporary social questions such as the free movement of people, the erosion of privacy, no-platforming and the increased political and social polarisation that is fuelled by social media. In re-examining the consequences for all of us of these attacks on free societies, Alexander calls for resistance to the forces of reaction. But he also calls for the concept of the Open Society to be rehabilitated and advanced. In doing this, he argues, there is an opportunity to re-think the kind of society we want to create, and to ensure it is achievable and sustainable. This forensic defence of the core principles of the Open Society is an essential read for anyone wishing to understand some of the powerful social currents that have engulfed public debates in recent years, and what to do about them. The book is publicly available via the following link The Open Society as an Enemy | LSE Press J. McKenzie Alexander is a Professor in Philosophy at the Department of Philosophy, Logic and Scientific Method in the London School of Economics. From 2012 to 2018, Professor Alexander served as one of the Academic Governors on the Council of the LSE, as well as a member of the Court of Governors. From 2018–2021, he served as the Head of Department. Before joining the department, Alexander was a Visiting Assistant Professor at the Department of Philosophy, University of California – San Diego (between 2000 and 2001). Although J. McKenzie Alexander's original field of research concerned evolutionary game theory as applied to the evolution of morality and social norms, more recently he has worked on problems in decision theory, more broadly construed, including topics in formal epistemology. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube Channel: https://www.youtube.com/user/a48266/videos Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

The Open Society as an Enemy: A critique of how free societies turned against themselves by J. McKenzie Alexander Nearly 80 years ago, Karl Popper gave a spirited philosophical defence of the Open Society in his two-volume work, The Open Society and Its Enemies. In this book, J. McKenzie Alexander argues that a new defence is urgently needed because, in the decades since the end of the Cold War, many of the values of the Open Society have come under threat once again. Populist agendas on both the left and right threaten to undermine fundamental principles that underpin liberal democracies, so that what were previously seen as virtues of the Open Society are now, by many people, seen as vices, dangers, or threats. The Open Society as an Enemy: A Critique of how Free Societies Turned Against Themselves interrogates four interconnected aspects of the Open Society: cosmopolitanism, transparency, the free exchange of ideas, and communitarianism. Each of these is analysed in depth, drawing out the implications for contemporary social questions such as the free movement of people, the erosion of privacy, no-platforming and the increased political and social polarisation that is fuelled by social media. In re-examining the consequences for all of us of these attacks on free societies, Alexander calls for resistance to the forces of reaction. But he also calls for the concept of the Open Society to be rehabilitated and advanced. In doing this, he argues, there is an opportunity to re-think the kind of society we want to create, and to ensure it is achievable and sustainable. This forensic defence of the core principles of the Open Society is an essential read for anyone wishing to understand some of the powerful social currents that have engulfed public debates in recent years, and what to do about them. The book is publicly available via the following link The Open Society as an Enemy | LSE Press J. McKenzie Alexander is a Professor in Philosophy at the Department of Philosophy, Logic and Scientific Method in the London School of Economics. From 2012 to 2018, Professor Alexander served as one of the Academic Governors on the Council of the LSE, as well as a member of the Court of Governors. From 2018–2021, he served as the Head of Department. Before joining the department, Alexander was a Visiting Assistant Professor at the Department of Philosophy, University of California – San Diego (between 2000 and 2001). Although J. McKenzie Alexander's original field of research concerned evolutionary game theory as applied to the evolution of morality and social norms, more recently he has worked on problems in decision theory, more broadly construed, including topics in formal epistemology. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube Channel: https://www.youtube.com/user/a48266/videos Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/gender-studies

Artificial intelligence is changing who can be a computer programmer. Leo Porter, professor of computer science and engineering at the University of California San Diego, explores how. Leo Porter is a Professor of Computer Science and Engineering at UC San Diego interested in computer science education research and computer architecture. Leo co-founded the Computing Education […]

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/lgbtq-studies

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/latin-american-studies

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/caribbean-studies

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/performing-arts

In Transformismo, M. Myrta Leslie Santana draws on years of embedded research within Cuban trans/queer communities to analyze how transformistas, or drag performers, understand their roles in the social transformation of the island. Once banned and censored in Cuba, transformismo, or drag performance, is now state-sponsored events. Transformismo suggests that these performances are making critical interventions in Cuban trans/queer life and politics and in doing so, the volume offers critical insight into how Cuba's postsocialist reform has exacerbated racial, sexual, and economic inequalities. Leslie Santana argues that mainstream trans/queer nightlife in Cuba is entangled with the island's tourism economy, which has shaped the aesthetics and social makeup of transformismo in coastal Havana, which largely caters to foreigners. Leslie Santana considers how Black lesbian and transgender transformistas are expanding understandings of sexual selfhood and politics on the island, particularly questioning the ways that Black women's creativity is prominently featured in the aesthetics of tourism and trans/queer nightlife, while Black women themselves are denied social and material capital. M. Myrta Leslie Santana is Assistant Professor of Music at the University of California San Diego. Katie Coldiron is the Outreach Program Manager for the Digital Library of the Caribbean (dLOC) and PhD student in History at Florida International University. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/anthropology

Send us a textLaura Christine Sainz is the CEO & Founder of Live Vegan Vibrantly (www.liveveganvibrantly.com, live.began.vibrantly on Insta), a transformational and healthy lifestyle coaching company that provides integrative medicinal practices and holistic services to teach, train, educate, and empower individuals to successfully thrive a healthy whole-food, plant-based lifestyle while living meaningful, passionate lives. In this episode of THE SOULFAM PODCAST,  Laura shares with Diana her long history of healing with food, consciousness and a deep understanding of her own body. Laura holds a Certificate in Excellent Customer Service, is Certified in High Performance Coaching, a Certified Level II Reiki Practitioner, Certified Bikram Yoga Teacher, an Enagic Distributor, holds a Bachelor's of Arts in Psychology and Spanish Literature from Arizona State University, and a trained Integrative Medicinal Cooking Instructor from the University of California San Diego. Laura managed her first real health crisis, Chrohn's Disease,  chronic inflammatory bowel disease, with food as her ally. Bedridden for almost two years, Laura struggled against the medical establishment's recommendations and soldiered onward with only her own intuition and deft ability as a researcher. She transformed not only her body but enriched her soul and mental and emotional welll-being through her understanding of food. As a master health and transformational lifestyle expert, world traveler, and educator, Laura works with top leaders in her field, inspiring individuals to take their lives to the next level to heal their bodies naturally to achieve optimal health and healing, while living the life of their dreams. Her unique approach combines mindset, emotional intelligence and psychology training, integrative medicinal practices, macrobiotics, whole-food, plant-based nutrition, raw cuisine, yoga, breathwork, self love and many more holistic healing practices depending on clients' needs. Laura also strong opinions and experiences relating to the medical field. Having recently watched her father pass in a less than ideal environment and dealing with her own medical and physical issues, Laura feels the US's current medical system fails society on many deep levels. Laura feels chronic diseases such as diabetes, Alzheimer's Disease and more can be addressed through our food sytem not our medical system. In this interview, AI -- whose notice on food packaging has become more common recently --  is also discussed with regard to its growing influence on bioengineered food.  In this interview, Laura does not hesitate to share her opinions, research and deep experiences. If this resonates with you, please share your comments, ideas and experiences. You can also contact Laura at her website, www.liveveganvibrantly.com and subscribe to her deeply researched newsletter which shares a wealth of health and food-related information monthly. Laura also works with groups, teaches online and is available for individual consultation. Laura's free monthly newsletter can be subscribed to on www.liveveganvibrantly.com . Please remember to like and subscribe on THE SOULFAM PODCAST with Diana. Grateful for every like, share and comment. It helps the podcast grow and for the voices of souls such as Laura be heard. THANKS!!! Support the show@dianamarcketta@lexisaldin

I am so excited to say that my guest on the GWA Podcast is the esteemed American artist, Lorna Simpson. Working across photography to painting, video to collage, Simpson is a multimedia artist who – since the 1980s – has gained widespread acclaim for her pioneering approach to conceptual photography. Whether it's fusing text with image, obscuring her subject's identity, using techniques such as repetition, collage or manipulation – Simpson has conjured a plethora of ways to reinvent the image, and, by doing so, raises questions about gender, race, memory, and history. Her work, mostly centred on the female body, is full of seemingly open-ended narratives – as she has said: “I think the idea of identity or persona is interesting to me in that it is malleable and fluid. And that has always been part of the work in terms of [thinking about] who gets to determine who we are. Do we get to determine that, and what are the parameters of that, given the society that we live in?” Engaging with found images and objects, whether that be cut-outs from Ebony or Jet Magazines, or photographs she finds on eBay, which she melds with inks or collages of jewels, Simpson has continuously reconfigured what painting and photography means. Born in 1960, and raised in Queens and Brooklyn in a childhood that put the arts first, Simpson received her BFA from the School of Visual Arts, New York, and following that, an MFA from the University of California San Diego, where she began to focus on the portraits of Black women she found in magazines, adding suggestive phrases from elsewhere. By 1990, she had a major exhibition at MoMA, and throughout the decades has continued to push boundaries with her seemingly limitless approach to materials. But in 2015, she turned to painting, showing her first nine-feet-tall canvases at the Venice Biennale, and this month will present a major exhibition – that considers the entirety of her painting practice – at the Metropolitan Museum of Art here in New York – where we are recording today. Titled “Source Notes”, it will feature Simpson's monumental and spellbinding paintings, which, steeped in monochromatic blues, silvers, blacks and greys, appear in settings that evoke the cosmological or natural world. An extension of her photographic work, Simpson's paintings see the manipulated figure and body pressed into landscapes akin to waterfalls or meteorites, and I can't wait to find out more… https://lsimpsonstudio.com/ Lorna Simpson: Source Notes –  https://www.metmuseum.org/exhibitions/lorna-simpson-source-notes?utm_source=google&utm_medium=cpc&utm_campaign=&utm_term=lorna%20simpson%20art&utm_content=39536&mkwid=s&pcrid=743882408399&pmt=b&pkw=lorna%20simpson%20art&pdv=c&slid=&product=&gad_source=1&gad_campaignid=22399716678&gbraid=0AAAAADmlGN7UtMbglt7UAR4dicGAOa9Vx&gclid=CjwKCAjw24vBBhABEiwANFG7ywIA72_JjPaxVUdfQSWW_h8NFYNWzddlSHz6KV38M9zgiG4rs_9UNxoCVFkQAvD_BwE https://www.hauserwirth.com/artists/2860-lorna-simpson/ -- THIS EPISODE IS GENEROUSLY SUPPORTED BY THE LEVETT COLLECTION: https://www.famm.com/en/ https://www.instagram.com/famm_mougins // https://www.merrellpublishers.com/9781858947037 Follow us: Katy Hessel: @thegreatwomenartists / @katy.hessel Sound editing by Mikaela Carmichael Music by Ben Wetherfield

Another food poisoning outbreak linked to McDonalds several months ago has taken a sinister new twist. One person died and 104 got infected by E. coli they caught from a popular menu-meal item sold at McDonald's restaurants. According to the CDCs National Center for Emerging Infectious Diseases, outbreaks, hospitalizations and deaths from E. coli are on the rise. A new studythis week from researchers at the University of California San Diego believethey've found a potential link between E. coli and colon cancer. Move Over, Meditation ‘New Wellness' Trend Taking Over TikTok' Meet Bed Rotting: Gen Z's viral obsession with spending entire days marinating in bed, doomscrolling and calling it ‘self-care.' Supporters say it's a mentalhealth reset; critics say it's glorified burnout with a side of crumpled Cheeto dust. Is this the ultimate recharge hack… or just a fancy term for avoiding adulthood? We dig into science (and the snacks) behind the movement.Dr. Bob and Dr. Brockman take calls and emails from listeners

Lorlatinib is reshaping first-line treatment for ALK-positive NSCLC—but its distinct side effect profile demands proactive, personalized management. In this episode,  Stefanie Houseknecht, PharmD, BCOP (Johns Hopkins Medicine) and Monica Chintapenta, PharmD, BCOP (Parkland Health)share how they're navigating real-world use of lorlatinib, from interpreting long-term data to counseling patients through CNS effects, weight gain, and metabolic challenges.Highlights:Why lorlatinib is gaining traction in first-line ALK+ NSCLCWhat the long-term CROWN data really means for patient outcomesHow to handle tricky side effects like cognitive changes, weight gain, and hyperlipidemiaReal-world tips for patient counseling and supporting adherenceThe importance of catching drug interactions and staying ahead on labsHow pharmacists are shaping care across the oncology teamBonus: Hear how our guests find balance beyond the clinic, whether in the garden or on the Boston marathon course. About Our Guests:Monica completed her Doctor of Pharmacy at Texas Tech University Health Sciences Center and went on to complete PGY-1 and PGY-2 residencies at Tufts Medical Center and Froedtert & the Medical College of Wisconsin, respectively. At Parkland, she supports outpatient hematology/oncology care and leads quality initiatives.   Stefanie earned her PharmD from the University of the Pacific, followed by PGY-1 and PGY-2 residencies at Palomar Medical Center and the University of California-San Diego. Her work focuses on thoracic malignancies, access to oral targeted therapies, and patient outcomes. She is active in the International Association for the Study of Lung Cancer and serves as a preceptor to pharmacy trainees across the Mid-Atlantic.  

When our good friends encounter challenges,A default response for many of us is often:To have their backTo show up fullyTo be kindTo put judgment aside, And to remind them that they are not alone. When we turn this practice, of being for someone, toward ourselves, particularly in the face of:obstacles, hardships, adversity, and failure,it's called self-compassion.A practice that involves recognizing our own suffering, and meeting it with love, As we learn to become a good friend to ourselves. Over time learning to listen less to the harsh whispers of the inner critic, And more to the encouraging words from that wiser part of us - Our inner ally.When we practice in this way, the door to a more sustainable and expansive experience opens, And we have the opportunity to walk through it and into the rest of our life with greater resilience, ease, wellbeing, and balance.Today's guest, Megan Prager, is Director of Compassion Programs at the University of California San Diego's Center for Mindfulness. Megan is one of the leading teachers of mindful self compassion in the US.She hosts retreats, classes, and experiences that offer the opportunity to learn mindfulness, compassion, and a whole host of practices that foster an opportunity to learn to become better friends to ourselves. Today we are going to take a deep dive into Megan's journey to becoming the teacher and leader she is today. A journey that was marked by her own experiences of adversity, suffering, and (particularly at the beginning) skepticism of the very practices she now teaches.We'll also get into the fiercer aspects of self-compassion that involve:Boundary setting, Fnding the courage to show up in integrity, And how self-compassion can be helpful in the challenging and uncertain times we find ourselves in. For more on Megan, her classes, retreats, teacher trainings, and various other offerings, please visit mindfullabs.comDid you find this episode inspiring? Here are other conversations we think you'll love:On Wholeness, Service, and Enduring Happiness | Stephanie HarrisonEmbracing the Journey From 'Doing' to 'Being' with Amy DongEnjoying the show? Please rate it wherever you listen to your podcasts. Thanks for listening!Support the show

Premiums are rising. Insurers are leaving markets. But people keep building in risk-prone areas, and the climate disasters just keep coming. Can insurance markets adapt? In this episode, Shayle talks to Dr. Judd Boomhower, an assistant professor of economics at the University of California-San Diego and a faculty research fellow at the National Bureau of Economic Research. He studies how insurance markets are reacting to climate change. Shayle and Judd cover topics like: Why insurers are limiting coverage in California, Florida, and other high-risk markets How disaster insurance, unlike auto or health insurance, faces a flood of claims all at the same time How catastrophe models (or “cat models” for short) work and why AI and other improvements struggle the solve the fundamental problem: a lack of historical data needed to predict future events The challenges of private “black-box” catastrophe models that can't be reviewed by third parties Reinsurance markets and why they're not attracting more capital to shore up insurers The pros and cons of parametric insurance, an emerging category of insurance products Undercapitalized “fly-by-night” insurers that risk insolvency and failing to pay out claim Recommended resources NBER: How Are Insurance Markets Adapting to Climate Change? Risk Classification and Pricing in the Market for Homeowners Insurance Brookings: “How is climate change impacting home insurance markets?” Credits: Hosted by Shayle Kann. Produced and edited by Daniel Woldorff. Original music and engineering by Sean Marquand. Stephen Lacey is executive editor. Catalyst is brought to you by Anza, a platform enabling solar and storage developers and buyers to save time, reduce risk, & increase profits in their equipment selection process. Anza gives clients access to pricing, technical, and risk data and tools that they've never had access to before. Learn more at go.anzarenewables.com/latitude. Catalyst is brought to you by EnergyHub. EnergyHub helps utilities build next-generation virtual power plants that unlock reliable flexibility at every level of the grid. See how EnergyHub helps unlock the power of flexibility at scale, and deliver more value through cross-DER dispatch with their leading Edge DERMS platform, by visiting energyhub.com.

There have been several headlines over the past week about an AI chatbot officially passing the Turing test. These news reports are based on a recent preprint study by two researchers at the University of California San Diego in which four large language models (LLMs) were put through the Turing test. One model, OpenAI’s GPT-4.5, was deemed indistinguishable from a human more than 70% of the time.

Cybersecurity remains a top concern for many healthcare organizations as attacks continue to increase. On today's Monday episode of the Gist Healthcare podcast, we hear the second part of host J. Carlisle Larsen's conversation with Christian Dameff, MD, emergency physician and Co-Director of the University of California-San Diego's Center for Healthcare Cybersecurity, about takeaways from last year's cyberattack on the Change Healthcare clearinghouse and how proposed federal legislation regarding healthcare cybersecurity could impact hospitals, especially in rural areas. You can listen to the first half of the conversation here. Hosted on Acast. See acast.com/privacy for more information.

The healthcare industry remains the most targeted sector for cyberattacks in the United States. Last year had the dubious distinction of having the most patient records exposed in a year at more than 276 million. It also had the largest healthcare cyberattack on record, when UnitedHealth Group's Change Healthcare was hacked in February. Though we know that hospitals, vendors, and related organizations are particularly vulnerable to attacks, it's been difficult to fully secure them. Christian Dameff, MD, emergency physician and Co-Director of the University of California-San Diego's Center for Healthcare Cybersecurity, joins host J. Carlisle Larsen to talk more about challenges facing the industry and some common misconceptions about the motivations behind these attacks. This is a two-part episode. The second half of their conversation will air on Monday, April 7. Hosted on Acast. See acast.com/privacy for more information.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Learning more about the FDA letter sent to Dexcom, news from ATTD including a bihormonal pump from a Dutch company, time in tight range update, more studies about using insulin and GLP-1 medications, eating chili to prevent gestational diabetes (really!) and more..  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week: Dexcom Dive Brief: A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom's continuous glucose monitors. The FDA raised concerns with a design change to a component used in the resistance layer of Dexcom's sensors. The sensors with the new component were less accurate than those with the original component, according to the warning letter. Dexcom has ceased distribution of G7 sensors with the component, but the company's response did not address affected G6 sensors. J.P. Morgan analyst Robbie Marcus wrote in a research note Tuesday that the letter concerns a chemical compound that the sensor wire is dipped in. Dexcom began producing the compound internally to add redundancy to its supply chain.   Dive Insight: Dexcom Chief Operating Officer Jake Leach said in an interview with MedTech Dive last week that the company does not expect the warning letter to affect future product approvals, including a 15-day version of its G7 CGM, and there's no need yet to recall products. Dexcom has submitted the device to the FDA and anticipates a launch in the second half of the year.   Marcus, after speaking to company leadership and a quality control expert, wrote that many of the issues outlined in the letter could be addressed quickly. He added that the warning letter could explain minor delays in approval to the 15-day sensor, but Dexcom is still within the 90-day window for a 510(k) submission.   “While there's always a risk this could impede future product approvals,” Marcus wrote, “we do not expect this to materially delay the 15 day G7 sensor approval.”   The warning letter followed an FDA inspection last year of Dexcom's facilities in San Diego and Mesa, Arizona. Marcus wrote that after the FDA requested additional information and a separate 510(k), Dexcom stopped in-sourcing the compound and reverted back to the external supplier.   Dexcom's devices were misbranded because the company did not submit a premarket notification to the FDA before making major changes to the sensors, according to the warning letter. The sensors with the changed coating “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions,” the letter said.     The FDA raised other concerns in the warning letter, including procedures to monitor the glucose and acetaminophen concentrations used in testing of the G6 and G7 CGMs. The FDA also cited problems with Dexcom's handling last year of a deficiency in its G6 sensors with dissolved oxygen content values, a key input for measuring blood glucose levels. https://www.medtechdive.com/news/dexcom-warning-letter-cgm-coating-change/743597/ XX Lots of studies and info out of the recent ATTD conference. One highlight that has been sort of under the radar: a Dutch company has been using a Bihormonal fully closed-loop system for the treatment of type 1 diabetes in the real world. This is a company called Inreda (in-RAY-duh). The Inreda AP® is an automatic system (closed loop) and independently regulates the blood glucose level by administering insulin and glucagon. The AP5 is certified in Europe and is being used in multiple studies and projects. The AP®6 is currently under development. https://www.inredadiabetic.nl/en/discover-the-ap/ https://pubmed.ncbi.nlm.nih.gov/38443309/ XX Let's talk about time in tight range. If you follow me and diabetes connections on social, you likely saw a video I made about this – it blew up last week. If not.. time in range has been a metric for a short while now.. in 2019 there was a consensus report advising a goal of 70% of time in the 70-180 mg/dL range for most people with type 1 diabetes (T1D) and type 2 diabetes (T2D), with modifications for certain subgroups. Recently we've been hearing more about 70-140 mg/dL — for longer periods as “time in tight range (TiTR).” At ATTD there was more talk about calling that range TING, or “time in normal glycemia.     There's a great writeup that I'll link up from the great Miriam Tucker on Medscape about a debate that happened at ATTD. On March 22, 2025, two endocrinologists debated this question at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025. Anders L. Carlson, MD, medical director of the International Diabetes Center (IDC), Minneapolis, took the positive side, while Jeremy Pettus, MD, assistant professor of medicine at the University of California San Diego, who lives with T1D himself, argued that it's too soon.   https://www.medscape.com/viewarticle/should-time-tight-range-be-primary-diabetes-goal-2025a100073q?form=fpf   XX Sequel Med Tech announces its twist pump will be firs paired with Abbott's FreeStyle Libre 3 Plus. The twist has FDA approval for ages 6 and up and is set to begin its commercial launch by the end of June. The pump—designed by inventor Dean Kamen's Deka Research & Development—also incorporates the FDA-cleared Tidepool Loop software program, to record CGM blood sugar readings, make predictions based on trends and adjust its background insulin levels accordingly. https://www.fiercebiotech.com/medtech/sequel-med-tech-connects-twiist-insulin-pump-abbotts-cgm-ahead-market-debut XX Dexcom's longer-lasting CGM sensor looks promising, based on study results presented at the conference. The trial showed that the new 15-day G7 system is slightly more accurate than the current G7. The accuracy of CGM can be measured using MARD (mean absolute relative difference), which shows the average amount a CGM sensor varies from your actual glucose levels (a lower number is better).  The 15-day G7 has a MARD value of 8.0%, about the same as the Abbott Freestyle Libre 3. The Dexcom G7 15 Day is awaiting FDA approval and is not yet available in the U.S.   XX Little bit of news from Modular Medical.. they plan to submit their patch pump to the FDA late summer or fall of this year. The MODD1 product, a 90-day patch pump, features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. It has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. Modular Medical picked up FDA clearance for MODD1 in September. The company also raised $8 million to end 2024. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. By developing its patented insulin delivery technologies, the company hopes to improve access to glycemic control. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. https://www.drugdeliverybusiness.com/modular-medical-announces-12m-private-placement/ XX More from attd – type 2 news? https://www.drugdeliverybusiness.com/biggest-diabetes-tech-news-attd-2025/ XX Another study that says people with type 1 who use a GLP-1 medication get better outcomes. In this study, those who use GLP-1 with insulin are 55% less likely to have a hyperglycemia-related ED visit, 26% less likely to have an amputation-related visit, and 29% less likely to have a diabetic ketoacidosis (DKA)-related ED visit in the following year compared to those on insulin alone. Although they are not approved for T1D, some patients may receive them off-label or for weight control. Pretty big study for an off label drug: compared 7,010 adult patients with T1D who were prescribed GLP-1s and insulin to 304,422 adult patients with T1D who were on insulin alone.  It is important to note that the rates of new diabetic complications in one year for both groups were around 1%, indicating that these are uncommon outcomes regardless of medication use. https://www.epicresearch.org/articles/some-diabetic-complications-less-likely-among-type-1-diabetics-on-glp-1s   XX Early research here but exposure to antibiotics during a key developmental window in infancy may stunt the growth of insulin-producing cells in the pancreas and boost risk of diabetes later in life The study, is published this month in the journal Science, it's a study in mice. These researchers are working off the idea that when while identical twins share DNA that predisposes them to Type 1 diabetes, only one twin usually gets the disease. She explained that human babies are born with a small amount of pancreatic “beta cells,” the only cells in the body that produce insulin.   But some time in a baby's first year, a once-in-a-lifetime surge in beta cell growth occurs.   “If, for whatever reason, we don't undergo this event of expansion and proliferation, that can be a cause of diabetes,” Hill said.   They found that when they gave broad-spectrum antibiotics to mice during a specific window (the human equivalent of about 7 to 12 months of life), the mice developed fewer insulin producing cells, higher blood sugar levels, lower insulin levels and generally worse metabolic function in adulthood.   in other experiments, the scientists gave specific microbes to mice, and found that several they increased their production of beta cells and boosted insulin levels in the blood. When male mice that were genetically predisposed to Type 1 diabetes were colonized with the fungus in infancy, they developed diabetes less than 15% of the time. Males that didn't receive the fungus got diabetes 90% of the time. Even more promising, when researchers gave the fungus to adult mice whose insulin-producing cells had been killed off, those cells regenerated. Hill stresses that she is not “anti-antibiotics.” But she does imagine a day when doctors could give microbe-based drugs or supplements alongside antibiotics to replace the metabolism-supporting bugs they inadvertently kill.   .   “Historically we have interpreted germs as something we want to avoid, but we probably have way more beneficial microbes than pathogens,” she said. “By harnessing their power, we can do a lot to benefit human health.”     https://www.eurekalert.org/news-releases/1078112 XX Future watch for something called BeaGL - created by researchers at the University of California Davis and UC Davis Health who were inspired by their own personal experiences with managing T1D.   BeaGL is designed to work with CGMs and has security-focused machine learning algorithms to make predictive alerts about anticipated glucose changes, which are sent to a device. In this case, a smartwatch. The end goal is for BeaGL to be completely automated to reduce the cognitive load on the patient, particularly for teens. It's still in research phase but six student with T1D have been using it for almost a year.     https://health.ucdavis.edu/news/headlines/with-ai-a-new-metabolic-watchdog-takes-diabetes-care-from-burden-to-balance/2025/02 XX Investigators are searching for a way forward after two long-term diabetes programs were terminated following the cancellation of their National Institutes of Health (NIH) funding, the result of federal allegations that study coordinator Columbia University had inappropriately handled antisemitism on campus. The programs include the three-decades-old Diabetes Prevention Program (DPP) and its offshoot, the Diabetes Prevention Program Outcomes Study (DPPOS). “We are reeling,” said David Nathan, MD, a previous chair of both the DPP and the DPPOS and an original leader of the landmark Diabetes Control and Complications Trial. Nathan is also founder of the Massachusetts General Hospital Diabetes Center in Boston, one of the 30 DPPOS sites in 21 states. On March 7, the Trump administration cancelled $400 million in awards to Columbia University from various federal agencies. While Columbia University agreed on March 21 to changes in policies and procedures to respond to the Trump administration's charges, in the hopes that the funding would be restored, DPPOS Principal Investigator Jose Luchsinger, MD, told Medscape Medical News that as of press time, the study was still cancelled. https://www.medscape.com/viewarticle/diabetes-prevention-program-cancellation-colossal-waste-2025a100076h XX XX Type 2 diabetes may quietly alter the brain in ways that mimic early Alzheimer's. This was only an animal study – but researchers say the high comorbidity of type 2 diabetes (T2D) with psychiatric or neurodegenerative disorders points to a need for understanding what links these diseases.   https://scitechdaily.com/how-diabetes-quietly-rewires-the-brains-reward-and-memory-system/ XX Eating chili once a month when you're pregnant seems to lower the risk of developing gestational diabetes. This is a real study! While chili showed a link to lower gestational diabetes risk, dried beans and bean soup had no significant effect, even among women who ate them more frequently. Some studies suggest that diets high in beans and legumes, including the Mediterranean diet, reduce GDM risk. While studies link beans to lower diabetes risk, their specific impact on GDM remains unclear. This study analyzed data from 1,397 U.S. pregnant women who participated in the Infant Feeding Practices Study II, conducted between 2005 and 2007. Chili consumption varied significantly by race, education, household size, income, supplemental nutrition status, and region. Non-Hispanic Black mothers consumed the most (0.33 cups/week), while those with higher income and education levels consumed less. Regional differences also influenced chili intake. One possible mechanism for chili's effect is capsaicin, a bioactive compound found in chili peppers, which has been linked to metabolic benefits in other studies. However, further research is needed to confirm this potential role in GDM prevention. Dried bean and bean soup consumption had no clear association with GDM. The study highlights limitations due to self-reported dietary data and the need for more detailed dietary measures. https://www.news-medical.net/news/20250317/Could-a-little-spice-in-your-diet-prevent-gestational-diabetes.aspx XX

Republican Missouri Rep. Peggy McGaugh wants to allow someone to serve up to 16 years in either the House or the Senate. Currently, most legislators can serve up to eight years in the House and eight in the Senate. McGaugh discusses her proposal on the Politically Speaking Hour on St. Louis on the Air. Then, term limits expert Thad Kousser, a political science professor at the University of California-San Diego, discusses the history and trends behind term limits in the U.S.

On the latest episode of the Politically Speaking Hour on St. Louis on the Air, STLPR's Jason Rosenbaum explores the pros and cons of Missouri's legislative term limits. He talked with state Rep. Peggy McGaugh, who wants to allow someone to spend up to 16 years in the Missouri House or the Missouri Senate. And he also discussed term limits throughout the country with University of California-San Diego political science professor Thad Kousser. Rosenbaum also checked in with GOP Rep. Eric Burlison about the lay of the land in Washington, D.C.

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Gerit D. Mulder to the podcast!  Dr. Mulder gave Dr. Jensen an opportunity to join his practice at the Wound Healing Institute after residency, providing a tremendous foundation for future research that included the National Institutes of Health, and Department of Defense opportunities.  Dr. Mulder has a storied history in podiatric medical research in the wound care space.  He received his BS at University of Redlands; a masters degree from Cal State - San Bernadino, then received his DPM from the College of Podiatric Medicine. He received his PhD from Chulalongkorn University through University of California San Diego specializing in Biomedical Sciences/Stem Cells.  Gerit speaks 5 languages and has taught wound care, and implemented wound care programs around the world.  Tune in for a fabulous interview! Below is a brief history of Dr. Mulder's activities and qualifications: • Extensive expertise in the development, implementation and management of clinical trials, clinical operations and teams.  Experience as a lead Principal Investigator interacting with and guiding multicenter trials.  Direct interaction with the FDA, Pharmaceutical Industry and Academic Research Centers.  Focus on Inflammatory Diseases, Dermatology and Infectious Disease.  • Responsible for development and oversight than 120 clinical trials. • Supervised, educated, and guided research teams globally. • Developed project budgets, protocols, guidelines, and implementation plans for developing wound clinics. • Provided strategic and tactical input to the medical industry related to clinical trials with emphasis on Phase 1,2 and 3 studies.  • Created tissue and wound repair programs to increase product understanding to assist Emerging Markets. Additional Expertise and Affiliations Include: • Understanding of Regulatory Affairs. • International experience with monitoring and overseeing clinical trials. • Served as a national and international  • Provided input on new product development for novel disease states.  • Conversational skills in English, Spanish, Italian, French, and German • Extensive experience with KOLs and medical advisory boards. Physician at Christus St. Vincent Medical Center, Wound & Hyperbaric Center. December 2021 to current. • Provide advanced clinical care for chronic wounds of all etiologies including diabetic, venous, pressure, trauma and other wounds. • Direct wound and tissue repair and regeneration research Medical Research Consultant – Independent 2019 – current Clinical Tissue Repair and Regeneration Specialist – 2019-current • Consult internationally on Phase 1,2, and 3 clinical trials • Provide input for development and implementation of clinical trials and educational materials for health care providers related to phase 1, 2 and 3 studies as well as approved products. • Provide clinical care to patients with acute and chronic wounds of all etiologies Director, Professor of Surgery and Orthopedics University of California San Diego Medical Center, Wound Treatment and Research Center   April 1998- December 2013 •  Provided clinical and surgical care, conducted medical student, resident and staff education, oversaw clinical research.  Treated more than 3000 patients per year.  Published in peer reviewed medical journals and key presenter at medical conferences globally. • Oversaw research within my division of the Department of Trauma, with focus on tissue regeneration and repair, inflammatory and infectious related diseases and cell regeneration. June 1986-April 1998: President of WCI (Wound Consultants Inc., previously Wound Healing Institute)    WCI offered consulting services to the biotechnology and pharmaceutical industry related to clinical protocols and trials, implementation of related patient care, planning and managing medical education.  Advised on development of new products related to tissue regeneration and repair. Patient Care    Vice President of Marketing and Medical Affairs DermaRx  May 1995- March 1998 Vice President of Clinical and Regulatory Affairs Organogenesis, Inc.   May 1994-May 1995     Wound Clinic Director Veterans Administration Hospital Denver June 1983- Jne 1992 FDA Experience: • Participated as an advisor to the FDA and companies working with the FDA • Completed and submitted 510k for hydrogel, foam, and other wound treatment devices • Completed clinical section of PMA submission on Apligraf for Organogenesis • Consulted as wound care expert on panels for medical and pharmaceutical industry. • Chaired Human Subjects Committee in Denver for two years for a major IRB. • Interacted with FDA on Dermatology and Inflammatory Diesease Dr. Mulder can be reached at (619) 417-9249 or at gerit.mulder@gmail.com;  gerit.mulder@stvin.org  or on LinkedIn at http://www.linkedin.com/pub/gerit-mulder/a/321/6b5

In this episode of the Next Level Healing Podcast, Dr. Tara Perry interviews Dr. Hemal Patel, Professor & Vice Chair for Research, Dept. of Anesthesiology at the University of California San Diego. Dr. Patel is well-known for his work with Dr. Joe Dispenza and his role in the movie, Source: It's Within You. This is an episode you don't want to miss!Work with Dr. Tara PerryTune in every week for a new episode of Next Level Healing. Subscribe on your favorite podcasting platform and never miss an episode!

One long-time expert on preventing student cheating argues that understanding why students cheat is key to making adjustments in teaching to prevent cheating with AI. It's the argument of Tricia Bertram Gallant, a longtime expert in academic integrity who is director of the Academic Integrity Office at the University of California San Diego who co-wrote a new book, “The Opposite of Cheating: Teaching for Integrity in the Age of AI. See show notes at EdSurge.com: https://www.edsurge.com/news/2025-01-07-ai-has-changed-student-cheating-but-strategies-to-stop-it-remain-consistent

Can transforming thoughts and beliefs lead to measurable changes in your health and wellbeing?I'm thrilled to share this week's conversation with Dr Joe Dispenza. Dr Joe is a New York Times best-selling author, researcher, lecturer, and corporate consultant, known for his transformative teachings on the power of the mind to heal and shape reality. Since 2010, Dr Joe has partnered with renowned scientists and universities – including University of California San Diego, Harvard University, Stanford University, and others – to perform extensive research on the effects of meditation on the brain and body.Inspired by the latest findings in neuroscience, psychoneuroimmunology, epigenetics, and quantum physics, Dr Joe teaches people worldwide to rewire their brains, break free from limiting patterns, and unlock their potential – all of which (and more) is showcased in his most recent film, SOURCE - It's Within You.If you're curious about how to harness the mind's power to alter your experience and achieve greater fulfillment, this conversation is one you're going to want to listen deeply to. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's Tuesday, December 3rd, A.D. 2024. This is The Worldview in 5 Minutes heard on 125 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Kevin Swanson Chinese democracy activists get prison time The Chinese Communist government in Hong Kong has sentenced 45 democracy activists to prison time. The activists had participated in a political party for a primary not approved of by the state. At least two Christians, Benny Tai, age 60, and Joshua Wong, age 28, were among those sent to prison. Finnish officials cancel concert featuring Handel's Messiah A school in the former Christian-influenced nation of Finland cancelled a concert featuring segments of Handel's Messiah.  According to a news report from the Helsingin Salomat paper, the cancelled concert would have been a joint performance by the Finnish Baroque Orchestra and the Helsinki Chamber Choir. Biden-Harris Dept of Ed. persecuting Christian colleges The American Principles Project has released a report charging the Biden administration's Department of Education with persecuting Christian colleges. The report cites that nearly 70% of penalties imposed by the Department of Education's Office of Enforcement has been against Christian institutions and career colleges, even though these schools represent less than 10% of college students. And, within the last year, the Biden-Harris Department of Education imposed record fines against two of the nation's most prominent Christian universities.  It fined Grand Canyon University a whopping $37.7 million for allegedly “not fully informing” students about the costs of its doctoral programs on its website. University officials “categorically” denied the allegation. And the education bureaucrats levied a $14 million fine against Liberty University for alleged violations which stem from a failure to comply with crime-reporting requirements.  The Department's penalty, the largest ever for the category, hardly fits the accusation— especially considering steps the school voluntarily took to remedy its reporting and agreed to spend $2 million towards “on-campus safety improvements and compliance enhancements.” By comparison, Michigan State University was only fined $4.5 million in 2019 for failing to report sexual abuses by former team doctor Larry Nassar, who assaulted hundreds of victims The fines of the Christian colleges amount to more than all other penalties assessed by the Department of Education over the past seven years. Also, the report points out that funding for the heavy-handed enforcement has increased from $4 million to $61 million just since 2023. Planned Parenthood gave hearts of aborted babies to scientists Stomach-churning emails show Planned Parenthood negotiating terms regarding the donation of aborted fetuses for medical research, reports the New York Post. The emails discuss fetal tissue like any other commodity such as sugar or rice, nonchalantly negotiating for dead babies who were alive up to 23 weeks gestation from elective abortions. A heavily-redacted so-called “Research Plan” submitted to the University of California San Diego Institutional Review Board, and approved in 2018, states scientists wanted 2,500 dead babies from up to almost the sixth month of gestation for experimentation.  The plan gruesomely states, “We will collect tissues from fetuses ranging from 4 to 23 weeks gestational age from subjects undergoing elective surgical pregnancy termination at Planned Parenthood in San Diego.” Although selling fetal tissue is illegal, donating it is not illegal. The contract between University of California San Diego and Planned Parenthood appears to allow Planned Parenthood to retain “intellectual property rights” relating to the fetal tissue, although it also does not grant the school the independent right to “commercialize” the tissue.  David Daleiden, pro-life journalist and the founder of the Center for Medical Progress, obtained the emails by filing a California public records request. Let's remember the words of Psalm 94:2-3, 6-7, 8-10.  “Rise up, O Judge of the Earth; repay to the proud what they deserve! O Lord, how long shall the wicked exult? They kill the widow and the sojourner, and murder the fatherless; and they say, ‘The Lord does not see; the God of Jacob does not perceive.' “Understand, O dullest of the people. Fools, when will you be wise? He who planted the ear, does He not hear? He who formed the eye, does He not see? He who disciplines the nations, does He not rebuke?” Joe Biden pardons his son In a surprising turn around, President Joe Biden pardoned his son, Hunter Biden, of several firearms charges, and “all crimes committed between 2014 and 2024,” which could have added up to 17 years prison time, reports The Associated Press. Gun control has played a major part in the 4-year Biden administration. Between 1993 and 2008, while serving in the US Senate, Joe Biden voted against gun rights on all nine bills presented. Democrat Congresswoman Jasmine Crockett of Texas cheered him on. CROCKETT: “Way to go, Joe. Let me be the first one to congratulate the president for deciding to do this. Because, at the end of the day, we know that we have a 34-count convicted felon that is about to walk into the White House. So, for anyone that wants to clutch their pearls now, because he decided that he was going to pardon his son, I would say, take a look in the mirror.” But Scott Jennings, the conservative commentator on CNN, was aghast. JENNINGS: “This is the worst possible thing a president could possibly do to his party and to the country. To sit for a year and say, ‘I will not do this. The rule of law is sacred. We have to respect the justice system. We have to respect juries. We have to respect the guard rails and the norms of our democracy.' “These people are liars. Inflation: it's transitory. Afghanistan: it's a success. The border is secure. Robert Hur is a liar. The videos are cheap fakes. Biden has a cold. He'll never drop out. ‘Oh, I'll never pardon Hunter.' It's all a lie. It is all a grift. “Every American -- except the most partisan, brain-rotted people -- are going to be outraged by this today. He's disgraced. Joe Biden, [White House Press Secretary] Karine Jean-Pierre, how many minutes of tape do we have of both of these people telling the American people this will not happen? We could play it all morning. And it's a lie to benefit his own family. “He's drained every ounce of credibility from every surrogate. If Karine Jean-Pierre had an ounce of self-respect, she'd get off the plane in Africa today, where they're going so he can avoid the press, and resign. He's drained all of her credibility and everybody else who's defended this.” Interestingly, prior to the election, in an interview with Hugh Hewitt, President-elect Donald Trump said he would consider a pardon for Hunter Biden. Biden censors God in Thanksgiving Proclamation In other President Biden news, for the second year in a row, he issued a Thanksgiving proclamation completely avoiding any mention of God, reports Breitbart. Thus far, only Presidents Barack Obama and Joe Biden have left God out of Thanksgiving. Romans 1:21 explains that “although they knew God, they did not glorify Him as God, nor were thankful, but became futile in their thoughts, and their foolish hearts were darkened.” Homosexual couples adopt at 7x the rate as heterosexual couples And finally, courts are awarding homosexual male couples and  homosexual female couples living together in sin with adoptions at seven times the rate of heterosexual married couples, according to recent data from the Census Bureau.  A full 21% of homosexuals living in a sinful relationship have adopted children.  Tragically, the Mark Regnerus study conducted in 2012 found that 8% of children raised in homosexual homes are victims of incest.  Close And that's The Worldview on this Tuesday, December 3rd, in the year of our Lord 2024. Subscribe by Amazon Music or by iTunes or email to our unique Christian newscast at www.TheWorldview.com. Or get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Could understanding the mystery of the Big Bang and how the Universe came into creation mean that we can finally know for sure if there is a creator? Professor Brian Keating is a cosmologist and experimental physicist at the University of California San Diego. He is the host of the ‘Into The Impossible' podcast and author of the books, ‘Losing The Nobel Prize' and ‘Into The Impossible: Think Like A Nobel Prize Winner'.  In this conversation, Brian and Steven discuss topics such as, how the discovery of the telescope changed the world, the link between our blood and the stars, the origins of the universe, and the scientific debate on God's existence.  (00:00) Intro (02:15) What Mission Are You On? (03:08) What Are Some Of The Most Controversial Questions You Set Out To Answer? (05:44) How Does God Tie Into The Creation Of The Universe Through A Scientific Lens? (08:26) $200 Million Project – Move Earlier (11:45) Meteor And 4-Billion-Year-Old Comet (15:38) Capturing The Origin Of The Universe (19:15) What Do You Suspect Is The Origin Of The Universe? (21:47) What Is The Most Compelling Evidence Of A God? (30:53) What Practices Help You Move Away From Being An Atheist? (39:09) Are We Searching For The Wrong Thing When It Comes To God? (41:30) If I Pray To This God, Will They Hear Me? (49:41) If It Was Proven God Wasn't Real, How Would Your Life Change? (53:48) What Is The Simulation Theory? (01:02:42) Do Aliens Exist? (01:17:45) What Is The Probability We're Alone? (01:24:31) Ads (01:25:31) Star Signs And Horoscopes (01:27:51) How Is Astrology Different From Religion? (01:30:07) What Is The Meaning Of Life? (01:32:43) What Was The Meaning Of Your Life Before Kids? (01:34:18) Do The Greats Feel Like Imposters? (01:40:13) The Importance Of Always Experimenting (01:41:09) Would You Ever Trade The Lack Of Privacy And Fame For Something Else? (01:43:25) The Last Guest's Question Follow Brian:  Instagram - https://bit.ly/4157xnt  Twitter - https://bit.ly/4eSKmjv  YouTube - https://bit.ly/4fQ9k4d  Podcast - https://bit.ly/3ZqRD5s  YouTube: You can purchase Brian's book, ‘Losing The Nobel Prize', here: https://amzn.to/4fOPR3M  Spotify: You can purchase Brian's book, ‘Losing The Nobel Prize', here: https://amzn.to/4fOPR3M  Watch the episodes on Youtube - https://g2ul0.app.link/DOACEpisodes  My new book! 'The 33 Laws Of Business & Life' is out now - https://g2ul0.app.link/DOACBook  You can purchase the The Diary Of A CEO Conversation Cards: Second Edition, here: https://g2ul0.app.link/f31dsUttKKb  Follow me: https://g2ul0.app.link/gnGqL4IsKKb Sponsors: Linkedin Jobs - https://www.linkedin.com/doac Learn more about your ad choices. Visit megaphone.fm/adchoices

As we enter our teenage years, many of us feel like life is just getting started. But for dogs, celebrating a ‘teen' birthday is a sign of old age, entering a phase when things start slowing down. Listener Susan was besotted with her beloved corgi Copper John and wants to know why our furry companions rarely live as long as us. We investigate what accounts for the huge differences in lifespans across animal species. From fish that live a few weeks, to sharks who can survive for 500 years, what are the factors that affect the ticking on our biological clocks? Central to this field is the idea of ‘live fast, die young', with some animals burning more quickly through their ‘life fuel'. But is this rate set in stone?Presenter Anand Jagatia find out how animals' growth, reproduction and anti-ageing methods contribute to the length of their survival. Dr Kevin Healy, a macroecologist at the University of Galway, discusses some of these theories, explaining how the dangers and luxuries faced by animals during their evolution shape their speed of life. One example of extreme slow living is the Greenland Shark. John Fleng Steffensen, Professor of Marine Biology at the University of Copenhagen, describes how he helped figure out how old they really are, and how their cold living quarters increase their lifespan. Alessandro Cellerino, physiologist at the Scuola Normale Superiore in Pisa, finds the key to the sharks' longevity in their DNA.Anand also goes on a hunt on the west coast of Ireland for a creature that lives fast but surprisingly, dies old. Noel Fahy, research student at the University of Galway, is his guide, while Dr Nicole Foley, Associate Research Scientist at Texas A&M University, reveals the life-extending secrets of this creature.And geneticist Trey Ideker, Professor at the University of California San Diego, busts the myth that one dog year is seven human years. But how much is this misconception off by?Presenter: Anand Jagatia Producer: Julia Ravey Content Editor: Cathy Edwards Studio Manager: Sarah Hockley Production Coordinator: Ishmael Soriano(Photo: Copper John the Welsh Pembrokeshire Corgi, by listener Susan)

If nations are to meet their sustainable energy goals, experts argue that batteries will be a crucial part of the equation. Not only are batteries key for many technologies, they'll also be necessary to meet energy demands with a power grid that is mainly supplied by renewable energy sources like wind and solar. Without batteries, power from those sources can't be stored for use when the sun isn't shining or the wind isn't blowing.Right now, many technologies depend on lithium-ion batteries. While they certainly work well and have revolutionized mobile devices and electric vehicles, there are drawbacks. First, the lithium, cobalt, and nickel they require can only be found in some countries, and there have been accusations of unethical mining practices, including child labor. The mining and production processes also emit a large amount of CO2, and the batteries themselves can explode and cause fires, although these incidents are becoming less common.A promising, greener solution to our battery needs could be something called a solid-state battery. Lithium-ion batteries conduct electricity through a liquid electrolyte solution, while solid-state batteries do so with solid materials, such as ceramic, glass, and sulfides. This means they have lower risk of fires, charge faster, have higher voltages, and can be recycled. However, their development has taken longer than expected, due to cost, production hurdles, and lack of large-scale, real-world testing.Earlier this month, teams at the University of Chicago Pritzker School of Molecular Engineering and the University of California San Diego published a paper in Nature Energy demonstrating the world's first anode-free, sodium-based, solid-state battery architecture, which can charge quickly and last for several hundred cycles. Its main ingredient, sodium, is much more abundant than lithium, cobalt, and nickel, which could mean more affordable and environmentally friendly batteries in the future.Ira Flatow sits down with Dr. Y. Shirley Meng, a professor at the University of Chicago Pritzker School of Molecular Engineering and chief scientist for energy storage science at Argonne National Laboratory, to talk about the advancement, and when we could expect to see these unique batteries in our devices.Transcript for this segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.